Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LSD1 Inhibitor
SP-2577 Seclidemstat · 1 trial · 1 indication
Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
| Arm | Type | Description |
|---|---|---|
| Sp-2577 | EXPERIMENTAL | Twice-daily administration of oral SP-2577 |
| Name | Type | Description |
|---|---|---|
| SP-2577 Seclidemstat | DRUG | Dose escalation and dose expansion of SP-2577. |
Inclusion Criteria: * Age ≥ 12 years and weight ≥ 40 kg. * Diagnosis of advanced or recurrent, histologically or cytologically confirmed, solid malignancy that is either metastatic or unresectable. At time of enrollment, subjects must have progressed on, be intolerant of, refuse, or ineligible for,...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SP-2577, also known as seclidemstat, is an investigational small molecule developed by Decoy Therapeutics Inc. (ticker DCOY) for advanced solid tumors. It is an LSD1 inhibitor and has been studied in a single Phase 1 clinical trial that is now completed.
SP-2577 Seclidemstat has been studied for the treatment of advanced solid tumors. Its clinical development has focused on oncology, and the one completed Phase 1 trial enrolled patients with advanced solid tumors in the United States.
SP-2577 Seclidemstat targets LSD1, also known as lysine-specific demethylase 1. It is described as an LSD1 inhibitor, a small molecule that acts on this epigenetic enzyme. The Phase 1 trial title identifies it as the LSD1 inhibitor SP-2577.
SP-2577 Seclidemstat is being developed by Decoy Therapeutics Inc., which trades under the ticker DCOY. The company is the sponsor associated with the drug's clinical development program in advanced solid tumors.
SP-2577 Seclidemstat is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
SP-2577 Seclidemstat has been evaluated in one clinical trial, NCT03895684, titled a Phase 1 trial of the LSD1 inhibitor SP-2577 (seclidemstat) in patients with advanced solid tumors. That trial is completed and enrolled 23 patients in the United States.